Maegim한국어

신풍제약

019170KOSPISector: Pharma & Biotech
₩7,690▼ 0.39%Market cap ₩403.1BAs of Jul 21, 2026 close · updated once daily
B
Grade B64.4 ptsTop 23% of 2,523 stocks
Financial strength
69.4
Growth momentum
68.0
Price attractiveness
56.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

69.4
How much debt does it carry relative to equity?
Debt-to-equity ratio
30.2%
✓ Above median · Top 29.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
309.0%
✓ Above median · Top 33.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
6.1%
✓ Above median · Top 26.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
3.3%
✓ Above median · Top 33.1% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

68.0
How much did revenue grow in a year?
Revenue growth (YoY)
6.1%
✗ Below median · Top 52.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
3.9%
✗ Below median · Top 54.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
169.7%
✓ Above median · Top 9.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
141.9%
✓ Above median · Top 11% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

56.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
45.7x
✓ Above median · Top 36% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.49x
✗ Below median · Top 51.8% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15